Loading...
research article
Perfluorinated HDAC inhibitors as selective anticancer agents
A series of potent histone deacetylase inhibitors is presented that incorporate alkyl or perfluorinated alkyl chains. Several new compounds show greater in vitro antiproliferative activity than the clinically approved inhibitor, SAHA. Furthermore, the new compounds show up to 5-fold greater activity against cancer cells than healthy cells. This selectivity is in contrast to SAHA, which is more active against the healthy cell line than the cancer cell line tested. Finally, we report an increase in activity for SAHA under mild hyperthermia, indicating that it could be an interesting candidate to use in combination with thermal therapy.
Type
research article
Web of Science ID
WOS:000414805900019
Authors
Publication date
2017
Publisher
Published in
Volume
15
Issue
43
Start page
9186
End page
9190
Peer reviewed
REVIEWED
EPFL units
Available on Infoscience
December 4, 2017
Use this identifier to reference this record